Dana-Farber Cancer Institute

Save the Date – The Fifth Transatlantic Exchange in Oncology: Transatlantic Innovations in Cancer Drug Research

In collaboration with @gustaveroussy.fr, the Fifth Transatlantic Exchange in Oncology will bring together leading cancer researchers and clinicians from the United States and Europe to explore transatlantic innovations in cancer drug research.

Learn more and register here: bit.ly/3MBh4xK

Xin Zhou, PhD, of Dana-Farber Cancer Institute

Congrats to @danafarbernews.bsky.social’s Xin Zhou, PhD, recipient of a 2026 Damon Runyon-Rachleff Innovation Award for "Extracellular reprogramming of kinase signaling pathways.” The award supports ideas with potential to impact the prevention, diagnosis, or treatment of cancer.

➡️ bit.ly/4rA75Il

Goldie Taylor

Following her recognition on Ragan's Top Women in Communications Class of 2026 list, @goldietaylor.bsky.social, Senior Vice President, Chief Communications and Marketing Officer, has been named to the 2026 Top Women in Communications Hall of Fame honorees list. Learn more: bit.ly/4rZDCap

Taming Chronic Inflammation | Dana-Farber Cancer Institute Dana-Farber researchers explore how lifestyle choices may help reduce cancer risk and improve outcomes

There is a growing understanding in cancer research that chronic inflammation may increase the risk of certain cancers, and that targeting inflammation may prevent cancer from recurring or developing in the first place. Learn how our researchers are advancing the science: bit.ly/3MD5GBt

Snowstorm closure announcement

Snowstorm update for Monday, February 23.

Naomi Lenane

Please join us in congratulating Naomi Lenane on being recently named to Becker's Healthcare's CIOs to Know 2026 list. View the list here: bit.ly/4qI2tOO

Alice Shaw, MD, PhD

Alice Shaw, MD, PhD, has been appointed to the George P. Canellos, MD, and Jean S. Canellos Professorship in Medicine at Dana-Farber and @harvardmed.bsky.social. Please join us in congratulating her on this well-deserved honor.

Researchers are using cutting-edge visual tools to understand how the immune system behaves in tumors. Learn more about how what they are learning could shape the future of cancer treatment: bit.ly/46tEBXX

Intriguing New Targets – Including GLP-1 – in Liposarcoma  New research uncovers promising targets, including the GLP-1 pathway, that may lead to new targeted therapies for liposarcoma.

Erica Pimenta, MD, PhD, working in @vanallenlab.bsky.social, studied molecular mechanisms that cause some liposarcomas to lose normal fat-cell functions and begin to spread, revealing new biological pathways, including GLP-1, that are now being explored in clinical research.

Forbes 2026 America's Best Large Employers List Forbes' list of America's Best Large Employers ranks the largest top companies to work for in 2026, featuring companies with the best benefits and best work-life balance.

We’re proud to be included in @forbes.com's 2026 Best Large Employer list. This recognition, based on employee sentiment, reflects our commitment to fostering a collaborative workplace where employees feel valued, supported, and empowered for long-term growth.

View the list here: bit.ly/403x3ri

TIME100 Health: Catherine Wu Find out why Catherine Wu is on the TIME100 Health 2026 list.

Congratulations to Catherine Wu, MD, on being recognized by TIME in the TIME100 Health 2026 list. Read more: bit.ly/4kEx3ru

Dana-Farber Research Helps Drive FDA Label Update for Primary CNS Lymphoma | Dana-Farber Cancer Institute Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that removes a prior exclusion for patients with primary central nervous system lymphoma, a rare and aggressive lymphoma of the brain and spinal cord. The change is expected to expand access to commercial CAR T-cell therapy for eligible patients with relapsed or refractory disease.

Dana-Farber-led research helped drive an @fda.gov label update for axicabtagene ciloleucel (Yescarta) that removes prior exclusion and may expand access to CAR T-cell therapy for eligible relapsed or refractory patients. Learn more: bit.ly/4rjfgbU

With deepest gratitude to Josh and Anita Bekenstein and the Jonathan and Jeannie Lavine family for their extraordinary generosity, long-standing partnership, and decades of dedication to our mission.

This extraordinary gift will help name and build the region’s only inpatient hospital dedicated to cancer, advancing a new, fully integrated model of cancer care centered on patients and families.

We are not just building a hospital, we’re raising the standard of cancer care for all.

A historic moment.

Last week, we announced the largest single gift in our history through a transformational joint commitment from Josh and Anita Bekenstein and the Jonathan and Jeannie Lavine family.

The Center for Global Health at Dana-Farber Cancer Institute is launching the first colorectal cancer screening program in Central Asia, partnering with Uzbekistan's Ministry of Health and National Cancer Center.

The Center for Global Health at @danafarbernews.bsky.social is excited to launch the first colorectal cancer screening program in Central Asia, partnering with Uzbekistan's Ministry of Health and National Cancer Center.

Read more here: bit.ly/4bzLivg

A purple graphic that reads "At least 40% of newly diagnosed cancers in U.S. adults are potentially avoidable."

Dana-Farber developed one of the first clinical cancer genetics and prevention programs in the world and remains one of the largest centers of its kind, providing expert, long-term, comprehensive care for cancer patients, survivors, and people seeking risk assessment and prevention care.

Leadership delegation from Dana-Farber and OncoClinic

We’re proud to announce a new strategic collaboration with OncoClinic to bring advanced and personalized oncology to Saudi Arabia. Learn more: bit.ly/4afscrT

Dr. Kimmie Ng of Dana-Farber Cancer Institute

The @washingtonpost.com recognized @danafarber.bsky.social's Dr. Kimmie Ng for her work in young-onset colorectal cancer. Dr. Ng is part of the 'Post Next 50,' the newspaper's annual look at 50 people shaping society in 2026.

Read more here: bit.ly/4kqFWob

Alice Shaw, MD, PhD

Kimberly Stegmaier, MD

Matthew Vander Heiden, MD, PhD

Congratulations to Alice Shaw, MD, PhD, Kimberly Stegmaier, MD, and Matthew Vander Heiden, MD, PhD, on being elected as Fellows of the @theaacr.bsky.social Academy Class of 2026. Learn more: bit.ly/45KykqC

We are deeply grateful for these two families’ decades-long dedication to our mission.

This week, we had the honor celebrating the largest single gift in our history: a transformative joint commitment from the Josh and Anita Bekenstein and Jonathan and Jeannie Lavine families to name and help build our future cancer hospital.

Vinayak Venkataraman, MD, of Dana-Farber Cancer Institute

ICYMI: Research by @danafarber.bsky.social's Vinayak Venkataraman, MD, in the Journal of Adolescent and Young Adult Oncology confirmed that #sarcoma and its treatment greatly disrupted the lives of #AYA patients – yet earlier introduction of support services may ease some challenges. bit.ly/3ZRpROT

Join us on Tuesday, February 24 at 6PM ET in Cambridge, MA (or online) for a Broad Discovery Series talk with Heidi Greulich and Matthew Meyerson, “The story behind a new therapy for lung cancer patients.” Register: broadinstitute.swoogo.com/Discovery26

A graphic that reads "Today is World Cancer Day" in blue font with colorful ribbons in the background.

A graphic that reads "At Rwanda's Butaro Cancer Center, Dana-Farber helped expand palliative care - bringing comfort and family support to patients." in blue font with colorful ribbons in the background.

A graphic that reads "Dana-Farber advanced prostate cancer research among Black men, helping improve risk awareness, culturally relevant screening, and care access." in blue font with colorful ribbons in the background.

A graphic that reads "Dana-Farber launched the EQUAL trial, using a new blood test to help detect cancerous lung tumors earlier in Asian and Hispanic/Latinx patients." in blue font with colorful ribbons in the background.

At @danafarber.bsky.social, we are reimagining the future of cancer care. This #WorldCancerDay, we're taking time to reflect on all the ways your generous support has helped make a difference around the globe. 🌎

The region's only inpatient hospital dedicated to cancer will be named in recognition of the remarkable joint gift. We are not just raising a building; we’re raising the standard of cancer care for all. To learn more, visit: bit.ly/3M3ny8n #WorldCancerDay

We are profoundly grateful to announce the largest single gift in our 78-year history through a new joint commitment from Josh and Anita Bekenstein and the Jonathan Lavine and Jeannie Lavine family.

Wally, the Red Sox mascot, walks through a room of people indoor cycling.

Thank you to the Pan Mass Challenge community for their commitment to raising incredible funds for cancer care and research! This past weekend, riders, volunteers, sponsors, and donors came together to be a part of the PMC Winter Cycle at Fenway Park.

2026 Transatlantic Exchange in Oncology Conference save the date graphic

The 2026 Transatlantic Exchange in Oncology Conference, hosted by Dana-Farber and @gustaveroussy.fr, will take place in Boston on March 27. This year’s event, co-chaired by @drchoueiri.bsky.social, MD, will focus on Transatlantic Innovations in Cancer Drug Research.

Register here: bit.ly/4bs5q2n

274 hospital and health system CNOs to know | 2025 Explore the 274 hospital health system CNOs leading nursing strategy and innovation in patient care across U.S. healthcare organizations in 2025.

Please join us in congratulating Anne Gross, PhD, RN, FAAN, who was recently named to Becker’s Hospital Review's CNOs to Know 2025. View the list here: bit.ly/4pUxpeh